Pharmacokinetics of Methotrexate in Children
Author Information
Author(s): A.D.J. Pearson
Primary Institution: University of Newcastle upon Tyne
Hypothesis
The study investigates the relationship between pharmacokinetics of methotrexate and clinical outcomes in children.
Conclusion
The study suggests that measuring methotrexate concentrations over 24 hours is sufficient to understand its pharmacokinetics and toxicity.
Supporting Evidence
- The study involved 127 patients to relate pharmacokinetics to clinical outcomes.
- Previous studies indicated that the AUC from 24 to 48 hours contributes less than 8% to the total AUC.
Takeaway
This study looked at how methotrexate behaves in children's bodies to see how it affects their treatment.
Methodology
Pharmacokinetic studies were conducted on methotrexate in 127 patients, measuring serum concentrations over a 24-hour period.
Limitations
Detailed pharmacokinetic studies were not possible in this large cohort due to practical constraints.
Participant Demographics
Children with acute lymphoblastic leukaemia.
Want to read the original?
Access the complete publication on the publisher's website